This study is looking at a new treatment called **[212Pb]Pb-MP0712** for adults with Small Cell Lung Cancer (SCLC) and other tumors that have a specific trait called **DLL3 expression**. The goal is to see if the treatment is safe and effective. Patients will receive doses of the treatment and be closely monitored for safety and how their tumors respond.
**Key Points for Participants:**
- The study is open to adults 18 or older with certain types of advanced cancer.
- Participants need to have had some previous cancer treatments that did not work well.
- Those with certain health conditions like uncontrolled illness or specific heart and lung issues may not be eligible.
**Important Details:**
The study has two parts: first to find the right dose, and second to learn more about how well it works and its safety. Participants will need to visit study centers for treatment and check-ups. Joining the study might help with understanding new cancer treatments, but there are risks since the treatment is still being tested.
How understandable was the trial content above?
Hard to understand
Easy to understand